Vanguard Global Advisers’s Summit Therapeutics SMMT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.05M Buy
61,876
+2,771
+5% +$41.4K ﹤0.01% 1685
2026
Q2
$861K Sell
59,105
-2,031
-3% -$36K ﹤0.01% 1831
2026
Q1
$1.16M Hold
61,136
– – ﹤0.01% 1557

Other funds holding SMMT

Vanguard Global Advisers's SMMT Position: Q3 2026 in Review

Vanguard Global Advisers increased its Summit Therapeutics (SMMT) stake by 4.7% in Q3 2026, buying an estimated $41.4K and bringing the position to 61,876 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #1685.

Vanguard Global Advisers first reported a position in SMMT in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.16M in Q1 2026. 298 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Vanguard Global Advisers held 61,876 shares of Summit Therapeutics worth $1.05M as of Q3 2026.
  • Vanguard Global Advisers bought 2,771 Summit Therapeutics shares in Q3 2026, an estimated $41.4K.
  • Summit Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1685 holding.
  • Vanguard Global Advisers first reported a position in Summit Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Summit Therapeutics position peaked at $1.16M in Q1 2026.
  • 298 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.